Riga

• A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients with Multiple Sclerosis Ended recruitment
  2023-505974-14-00 5 2022-06-23 Multiple Sclerosis (MS)
• Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis, followed by long term treat … Ended recruitment
  2023-509345-12-00 5 2022-06-22 Multiple Sclerosis
• A Placebo-Controlled Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Atherosclerotic Cardiovascular Disease … Ended recruitment
  2023-507795-51-00 5 2022-05-17 atherosclerotic heart and blood vessel disease (the narrowing of arter
• A Phase 3 Single-Arm Study of UGN-102 for Treatment of LG IR NMIBC Ended recruitment
  2023-506680-34-00 5 2022-03-24 Non-Muscle Invasive Bladder Cancer
• A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison with Fingolimod in Children and Adolescents with Relapsing-Remitting Mu … Ended recruitment
  2023-506516-40-00 5 2022-02-11 Relapsing-Remitting Multiple Sclerosis
• A research study to find out whether a medicine called inclisiran helps to prevent cardiovascular death, heart attacks or strokes in people … Ended recruitment
  2024-510735-21-00 5 2021-11-26 Atherosclerotic cardiovascular disease (ASCVD)
• ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease … Ended recruitment
  2023-506926-35-00 5 2021-09-24 Atherosclerotic cardiovascular disease, chronic kidney disease and sys
• A Study of the Efficacy and Safety of Guselkumab in Participants with Active Psoriatic Arthritis Ended recruitment
  2023-504734-21-00 5 2021-08-30 Psoriatic arthritis (PsA)
• An open study for participants who have been on darolutamide treatment in any other Bayer study Ended recruitment
  2022-502084-38-00 5 2020-10-16 Cancer
• Long-term study to assess the safety and efficacy of Nemolizumab in subjects with Atopic Dermatitis Ended recruitment
  2024-514404-13-00 5 2020-10-01 Atopic Dermatitis
• A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn’s Disease (VIVID-2) Ended recruitment
  2022-502841-91-00 5 2020-08-12 Crohn’s Disease
• Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell … Ended recruitment
  2023-503591-25-00 5 2020-06-09 Non-small cell lung cancer
• Phase III study of Pembrolizumab plus chemoradiation vs chemoradiation along for patients with muscle invasive bladder cancer Ended recruitment
  2023-503500-87-00 11 2020-03-17 Muscle Invasive Bladder Cancer
• Olaparib in combination with pembrolizumab in HRRm and HRD positive cancer Ended recruitment
  2023-503831-17-00 4 2019-12-23 The treatment of participants with HRRm and/or HRD-positive cancer
• A Study of the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis Ended recruitment
  2023-504718-31-00 10 2019-10-19 Moderately to Severely Active Ulcerative Colitis
• An open label, multicenter extension study in patients previously enrolled in a Genentch and/or F. Hoffmann-La Roche Ltd sponsored atezolizu … Ended recruitment
  2023-506184-34-00 5 2019-08-09 Advanced Malignancies
• A research study in children born small and who stayed small. Treatment is somapacitan once a week compared to Norditropin® once a day Ended recruitment
  2023-506830-66-00 4 2019-05-29 SGA - small for gestational age children
• A Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or … Ended recruitment
  2023-505478-14-00 5 2019-05-09 Psoriatic Arthritis
• A research study to look at how semaglutide compared to placebo affects diabetic eye disease in people with type 2 diabetes (FOCUS) Ended recruitment
  2023-506827-26-00 5 2019-05-02 While it is well-established that long-term good glycaemic control wil
• An open-label extension study evaluating long-term safety, tolerability and effectiveness of ofatumumab in subjects with RMS Ended recruitment
  2023-507906-15-00 5 2019-01-30 Relapsing multiple sclerosis (RMS)
• A Study to Assess the Efficacy and Safety of Risankizumab in Subjects with Ulcerative Colitis Ended recruitment
  2023-506994-36-00 5 2018-10-11 Ulcerative Colitis
• LUCENT-3 Extension Study of Mirikizumab in Ulcerative Colitis Ended recruitment
  2023-507657-15-00 5 2018-09-13 Ulcerative Colitis
• A Study of the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Crohn's Disease Ended recruitment
  2023-504736-18-00 10 2018-07-26 Moderately to Severely Active Crohn's Disease
• Chemo +/- Pembrolizumab (MK-3475) as Perioperative Therapy for Stage II, IIIA-Resectable IIIB (N2) NSCLC Ended recruitment
  2023-504820-24-00 5 2018-03-21 Neoadjuvant/Adjuvant treatment for participants with Resectable Stage

Showing 97–120 of 192 trials